A sensitive HPLC-MS-MS method for the determination of raltegravir in human plasma.
about
Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapyRaltegravir pharmacokinetics in neonates following maternal dosingGenetic and non-genetic determinants of raltegravir penetration into cerebrospinal fluid: a single arm pharmacokinetic study.An accurate and precise high-performance liquid chromatography method for the rapid quantification of the novel HIV integrase inhibitor raltegravir in human blood plasma after solid phase extractionPopulation pharmacokinetic analysis of raltegravir pediatric formulations in HIV-infected children 4 weeks to 18 years of agePharmacokinetics and 48-Week Safety and Efficacy of Raltegravir for Oral Suspension in Human Immunodeficiency Virus Type-1-Infected Children 4 Weeks to 2 Years of AgeSimultaneous measurement of etravirine, maraviroc and raltegravir in pigtail macaque plasma, vaginal secretions and vaginal tissue using a LC-MS/MS assay.Does Once-Daily Raltegravir Have Any Role in the Antiretroviral Treatment?Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-infected children aged 2 through 18 years.A sensitive liquid chromatography coupled with mass spectrometry method for the intracellular and plasma quantification of raltegravir after solid-phase extraction.Selective and rapid determination of raltegravir in human plasma by liquid chromatography-tandem mass spectrometry in the negative ionization mode.
P2860
Q33962223-C67DCE54-56B0-4138-A621-A497014CD8D3Q34339266-5D58810F-E29A-4C37-87AA-D7E3E985FA9CQ35070434-7F4833E7-00AD-41F7-A219-9B62486A3C40Q35781692-5993313E-1563-4C44-BF32-6F10790AB763Q36066766-0E480701-7959-4F64-B648-900DA5BFDF9BQ36377397-5E91B8D3-52B7-4061-8C40-775B2E5A7F93Q37042100-C2ED12A0-7C25-4AAF-9D89-89057222D6F1Q37176168-DB962669-4DBF-4FA5-A85E-0F8BC494CEEFQ37473017-359BC2D7-C7BA-4159-8F9E-DAD561CA4E1AQ44660027-0630651F-713F-40D2-BAD0-E456F7EDCAC1Q49224464-91D45151-20A6-476F-81DE-DA2D1181E9CE
P2860
A sensitive HPLC-MS-MS method for the determination of raltegravir in human plasma.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
A sensitive HPLC-MS-MS method for the determination of raltegravir in human plasma.
@en
A sensitive HPLC-MS-MS method for the determination of raltegravir in human plasma.
@nl
type
label
A sensitive HPLC-MS-MS method for the determination of raltegravir in human plasma.
@en
A sensitive HPLC-MS-MS method for the determination of raltegravir in human plasma.
@nl
prefLabel
A sensitive HPLC-MS-MS method for the determination of raltegravir in human plasma.
@en
A sensitive HPLC-MS-MS method for the determination of raltegravir in human plasma.
@nl
P2093
P1476
A sensitive HPLC-MS-MS method for the determination of raltegravir in human plasma.
@en
P2093
Chantelle Bennetto-Hood
Edward P Acosta
Mary C Long
P304
P356
10.1016/J.JCHROMB.2008.03.022
P577
2008-04-01T00:00:00Z